title: The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
abstract: We studied blood and bone marrow cells from 42 patients with Ph-chromosome positive chronic myeloid leukemia (CML) and 20 normal subjects for amplification of the multidrug resistance gene (MDR-1) by Southern blotting and for overexpression of P-glycoprotein (P-170) by immunocytochemistry on intact cells with the monoclonal antibody C219. No P-170 could be detected in normal bone marrow or buffy coat. Overexpression of P-170 without amplification of MDR-1 was found in four of 11 patients with chronic phase CML at diagnosis, seven of 16 patients treated with busulfan or hydroxyurea in chronic phase and four of 15 patients in blast crisis. The P-170 overexpression involved only cells of the granulocyte lineage and varied from weak to strong in individual patients. It did not correlate with duration of or response to treatment during chronic phase. In transformation P-170 expression was seen in differentiated cells of the granulocyte lineage but not in blast cells, although three patients had been treated intensively with lipophilic and other cytotoxic drugs to which they had become resistant. We conclude that resistance to busulfan and hydroxyurea in chronic phase and resistance of blast cells to other cytotoxic drugs in transformation are not mediated primarily through the MDR-1/P-170 pathway.
authors.affiliation: MRC Leukaemia Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.
authors.forename: R
authors.initials: R
authors.lastname: Weide
authors.forename: C
authors.initials: C
authors.lastname: Dowding
authors.forename: W
authors.initials: W
authors.lastname: Paulsen
authors.forename: J
authors.initials: J
authors.lastname: Goldman
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D002066:Busulfan / Q000627:therapeutic use; D004351:Drug Resistance / Q000235:genetics*; D005784:Gene Amplification; D015870:Gene Expression; D005796:Genes; D006098:Granulocytes / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000378:metabolism / Q000502:physiology*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D008562:Membrane Glycoproteins; D002066:Busulfan; D006918:Hydroxyurea